Search Results - "Schejbalová, Stanislava"
-
1
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Published in Clinical and experimental pharmacology & physiology (01-12-2010)“…Summary 1. Hypertension plays a critical role in the progression of chronic kidney disease (CKD) to end‐stage renal disease (ESRD), but it has also been…”
Get full text
Journal Article -
2
Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats
Published in Vascular pharmacology (01-08-2007)“…Abstract The aim of the present study was to evaluate the effects of inhibition of cytochrome P-450 (CYP) activity by 1-aminobenzotriazole (ABT) and by CoCl2 ,…”
Get full text
Journal Article -
3
AT1 receptor antisense therapy transiently lowers blood pressure in Ren-2 transgenic rats
Published in Vascular pharmacology (01-07-2007)“…Abstract The effectiveness of antisense (AS) phosphorothioated oligodeoxynucleotides (AS-ODN) targeted to the angiotensin (ANG) type 1 (AT1 ) receptor, was…”
Get full text
Journal Article -
4
Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats
Published in Vascular pharmacology (01-09-2006)“…Male heterozygous Ren-2 transgenic rats and Hannover Sprague–Dawley rats fed a normal or high-salt diet were either untreated or treated with the nonselective…”
Get full text
Journal Article -
5
Long-term prevention of hypertension and end-organ damage in Ren-2 transgenic rats is achieved only with persistent but not transient AT1 receptor blockade
Published in Kidney & blood pressure research (2007)“…The aim of this study was first to evaluate the effects of persistent or transient blockade of the angiotensin II (ANG II) receptor AT(1) on the development of…”
Get more information
Journal Article -
6
AT 1 receptor antisense therapy transiently lowers blood pressure in Ren-2 transgenic rats
Published in Vascular pharmacology (2007)“…The effectiveness of antisense (AS) phosphorothioated oligodeoxynucleotides (AS-ODN) targeted to the angiotensin (ANG) type 1 (AT 1) receptor, was studies in…”
Get full text
Journal Article